ArcherDX


ArcherDX is a life sciences tools company that sells kits and software to researchers and clinicians to improve the speed and precision of sequence results.
CO-INVESTOR
OUTCOME:
Invitae Reports $116.3 Million in Revenue Driven by 287,000 in Billable Volume in Second Quarter of 2021
SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced preliminary financial and operating results for the second quarter ended June 30, 2021 and increases 2021 guide to revenue between $475-$500 million for the year.
Read moreInvitae opens early access to liquid biopsy-based Personalized Cancer Monitoring as a central laboratory service
SAN FRANCISCO, June 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has begun offering early access to its new Personalized Cancer Monitoring (PCM™) platform as a laboratory-developed test performed at an Invitae central laboratory.
Read moreInvitae Reports $103.6 Million in Revenue Driven by 259,000 in Billable Volume in First Quarter of 2021
SAN FRANCISCO, May 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021.
Read moreThe Evolution of Genetic Diagnostics: Shifting from ‘Value-Enabling’ to a ‘Value-Driving’ Paradigm
Over the past 40 years, the vast majority of therapeutics that entered human testing failed to make it to market. Over the past 20 years – and really accelerating over the past 5 years – new technologies and clinical development strategies emerged that made it possible to dramatically improve on those historically dismal rates. “Precision medicine” holds the promise of the right medicine for the right patient at the right time, and represents a paradigm change from the empirical medicine…
Read moreInvitae Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or…
Read moreLeading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is…
Deal of the Year CBSA Awards Celebration 2020
Jason Myers and his team were honored at the CBSA awards banquet last week with the Deal of the Year Award, a well-deserved honor. See video linked in the title of this article and embedded within.
Read moreInvitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment.
ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock
BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring.
Read moreArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research
BOULDER, Colo., June 18, 2020 /PRNewswire/ – ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy.
Read moreArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
BOULDER, Colo., May 26, 2020 /PRNewswire/ — ArcherDX, Inc., today announced a strategic collaboration with AstraZeneca to develop assays to support multiple planned Phase 3 clinical trials for AstraZeneca’s targeted immuno-oncology therapeutics.
Read moreArcherDX's first Cdx Approval in Japan for Merck KgA's Tepotinib
BOULDER, Colo., March 25, 2020/PRNewswire/ — ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Medical Devices Agency (PMDA) to detect MET exon 14 ( MET ex14) skipping alterations in tissue (RNA) and liquid biopsy (ctDNA) from patients with advanced non-small cell lung cancer (NSCLC) for consideration for treatment with Merck KGaA, Darmstadt, Germany’s oral MET…
Read moreArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests
Co-marketing partnership to drive awareness of ArcherDX IVD products and increase access to vital genomic information in the community oncology care setting
Read moreArcherDX Announces Close of $55 Million Series C Financing
ArcherDX, Inc., a molecular diagnostics company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced the close of a $55 million Series C financing.
Read moreArcherDX Announces the Appointment of Steven J. Kafka, Ph.D. as Executive Chairman of the Board of Directors
ArcherDX, Inc., today announced the appointment of Steven J. Kafka, Ph.D. as executive chairman of the ArcherDX board of directors.
Read moreArcherDX Announces Close of $60M Financing
ArcherDX, Inc. today announced the closing of an up to $60 million Series B financing round led by Perceptive Advisors. The investor syndicate also includes existing investors PBM Capital, Boulder Ventures, Longwood Fund and Peierls Foundation.
Read more